Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Denosumab Trial Met Primary and All Secondary Endpoints by Significantly Delaying Time to First Skeletal Related Event and Significantly Reducing First-and-Subsequent Skeletal Related Events...
Fourth Quarter 2009 Revenue Increased 2 Percent to $3.8 Billion; Full Year 2009 Revenue Decreased 2 Percent to $14.6 Billion Fourth Quarter 2009 GAAP Earnings Per Share Increased 6 Percent to...
THOUSAND OAKS, Calif., Jan. 21 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in...
THOUSAND OAKS, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 25, 2010...
Company, Staff Contributions To Help Haitian Victims THOUSAND OAKS, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that the company will donate $2 million to Haiti...
THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) will present at the 28th Annual JP Morgan Global Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. 12...
Roche Admits Infringement And Validity Of Amgen's EPO Patents; Court Enters Permanent Injunction; Amgen Allows Roche's MIRCERA Onto U.S. Market In Mid-2014 THOUSAND OAKS, Calif., Dec. 22...
THOUSAND OAKS, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) announced today that Roger M. Perlmutter, M.D., Ph. D., Amgen's executive vice president of Research & Development...
THOUSAND OAKS, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that its board of directors has authorized repurchases of up to an additional $5 billion in Amgen...
Applications for 2010 Amgen Scholars U.S. and Europe Programs Now Available THOUSAND OAKS, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Each year, hundreds of undergraduate students from across the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
